Pharmaceutical Care
Management Association
325 7th Street, NW
Washington, DC 20004
Main: 202.756.5700
©2024 PCMA. All Rights Reserved.
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on a new report from IQVIA Institute for Human Data Science, 2018 and Beyond: Outlook and Turning Points. Key findings from the report include: Rebates and discounts
PBMs Support and Encourage Biosimilar Competition Increased biosimilar competition drives down prescription drug costs Having multiple biosimilar and reference biologic competitor products with equivalent patient benefits on the market allows pharmacy benefit companies, PBMs, to push manufacturers to compete on
(Washington, D.C.) — Senior registered voters enrolled in Medicare Part D will be less likely to support the reelection of their members of Congress and presidential candidates if those elected officials back proposals eliminating prescription drug negotiations and price concessions
The Medicare Prescription Drug Rebate Rule PCMA Urges Congress to Permanently Repeal Rebate Rule This Year The Medicare Part D prescription drug benefit provides our nation’s seniors with affordable drug coverage, which is more important now than ever. The rebate
(Washington, D.C.) — As drugstore lobbyists descend on Albany today, it is important to highlight how pharmacy benefit managers (PBMs) advocate for consumers and health plan sponsors in the fight to keep prescription drugs accessible and affordable. It is equally
(Washington, D.C.) — The Pharmaceutical Care Management Association released the following statement on the Pennsylvania Auditor General’s report, “Bringing Transparency & Accountability to Drug Pricing:” “The Pennsylvania Auditor General has released yet another biased report on pharmacy benefit managers (PBMs).
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Health and Human Services Office of Inspector General’s proposed rule on prescription drug rebates in Medicare: “While we are reviewing the proposed
©2024 PCMA. All Rights Reserved.